CLAIMS

1. A composition comprising niraparib in an amount of about 50 mg to about 350 mg based on the niraparib free base,

wherein the composition is a pharmaceutical composition formulated as a tablet comprising an intragranular phase and an extragranular phase, and wherein:

(a) at least one component of the intragranular phase is a diluent, a binder, a disintegrant, a glidant, or a lubricant; and/or

(b) at least one component of the extragranular phase is a disintegrant, a glidant, or a lubricant; and

wherein the composition comprises a binder.

2. A composition comprising niraparib tosylate monohydrate in an amount of about 100 mg to about 550 mg,

wherein the composition is a pharmaceutical composition formulated as a tablet comprising an intragranular phase and an extragranular phase, and wherein

the composition comprises niraparib tosylate monohydrate in an amount that is about 40-50% by weight of the tablet composition; and

wherein the composition comprises a binder.

3. The composition of claim 2, wherein the intragranular phase comprises a diluent in an amount that is about 7.5-15%, about 8-14%, or about 9-11% by weight of the tablet composition.

4. The composition of claim 3, wherein the intragranular phase comprises a second diluent in an amount that is about 25-40%, about 30-40%, or about 30-35% by weight of the tablet composition.

5. The composition of any one of claims 2-4, wherein the intragranular phase comprises a binder in an amount that is about 1-3% by weight of the tablet composition.

6. The composition of any one of claims 2-5, wherein the intragranular phase comprises a disintegrant in an amount that is about 0.1-2% or about 0.5%-1.5% by weight of the tablet composition.

7. The composition of any one of claims 2-6, wherein the intragranular phase comprises a glidant, adsorbant, or absorbant in an amount that is about 1-5% or about 2-4% by weight of the tablet composition.

8. The composition of any one of claims 2-7, wherein the intragranular phase comprises a lubricant in an amount that is about 0.1-2% by weight of the tablet composition.

9. The composition of any one of claims 2-8, wherein the extragranular phase comprises a distintegrant in an amount that is about 0.1-2% by weight of the tablet composition.

10. The composition of any one of claims 2-9, wherein the extragranular phase comprises a glidant or adsorbant or absorbant in an amount that is about 0.1-2% by weight of the tablet composition.

11. The composition of any one of claims 2-10, wherein the extragranular phase comprises a lubricant in an amount that is about 0.1-2% by weight of the tablet composition.

12. A composition in the form of a tablet comprising the following components on a weight percentage basis:

(a) in an intragranular portion:

(i) 40-50% niraparib tosylate monohydrate;

(ii) 9-11% of a first diluent;

(iii) 30-40% of a second diluent;

(iv) 1-3% of a binder;

(v) 0.1-2% of a disintegrant;

(vi) 2-4% of a glidant or adsorbant or absorbant; and

(vii) 0.1-2% of a lubricant;

(b) in an extragranular portion:

(i) 0.1-2% of a disintegrant;

(ii) 0.1-2% of a glidant or adsorbant or absorbant; and

(iii) 0.1-2% of a lubricant.

13. The composition of claim 12, wherein the lubricant is magnesium stearate.

14. The composition of claim 12 or claim 13, wherein the disintegrant is crospovidone.

15. The composition of any one of claims 13-14, wherein the glidant is silicon dioxide, optionally wherein the glidant is intermediate meso-porous silica, further optionally wherein the intermediate meso-porous silica comprises colloidal silica.

16. A composition in the form of a tablet comprising
    (a) an effective amount of niraparib to inhibit polyadenosine diphosphate ribose polymerase (PARP) when administered to a subject in need thereof;
    (b) a first diluent selected from lactose monohydrate, lactose anhydrous, mannitol, and calcium phosphate dibasic;
    (c) magnesium stearate;
    (d) a second diluent selected from microcrystalline cellulose, starch, polyethylene oxide, and hydroxypropyl methylcellulose (HPMC); and
    (e) a binder selected from povidone (PVP), hydroxypropyl cellulose (HPC), and hydroxypropyl methylcellulose (HPMC).

17. The composition of any one of claims 12-16, wherein the first diluent is lactose monohydrate.

18. The composition of any one of claims 12-17, wherein the second diluent is microcrystalline cellulose.

19. The composition of any one of claims 12-18, wherein the binder is povidone (PVP).

20. The composition of any one of claims 12-19, wherein the disintegrant is crospovidone or croscarmellose.

21. The composition of any one of claims 1-20, wherein the composition further comprises silicon dioxide.